Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population

International Journal of Hematology

Volumn 89, Issue 4, 2009, Pages 445-451

  Zhao, Yanmin ^a   Liu, Lizhen ^a   Wang, Yingjia ^a   Wu, Gongqiang ^a   Lai, Xiaoyu ^a   Cao, Weijie ^a   Luo, Yi ^a   Tan, Yamin ^a   Shi, Jimin ^a   Xie, Wanzhuo ^a   Ye, Xiujin ^a   Cai, Zhen ^a   Lin, Maofang ^a   Huang, He ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Chinese population; Chronic myeloid leukemia; Cytogenetic response; Hypopigmentation; Imatinib; Prognosis

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHILD; CHINESE; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HYPOPIGMENTATION; KARYOTYPE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; PROGNOSIS; SCHOOL CHILD; SIDE EFFECT; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT RESPONSE; CHINA; DISEASE COURSE; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; CHINA; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PYRIMIDINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67449123241     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0292-7     Document Type: Article

References (21)

1. I Nash 1999 Chronic myeloid leukemia N Engl J Med. 341 765 10.1056/NEJM199909023411016 (Pubitemid 29407384)
2. H Kantarjian C Sawyers A Hochhaus 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med. 346 645 652 10.1056/NEJMoa011573 (Pubitemid 34815868)
3. BJ Druker F Guilhot SG O'Brien 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med. 355 2408 2417 10.1056/NEJMoa062867 (Pubitemid 44903745)
4. Z Aziz J Iqbal M Akram 2007 Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country Cancer. 109 1138 1145 10.1002/cncr.22498 (Pubitemid 46435393)
5. S Rajappa L Varadpande T Paul 2008 Imatinib mesylate in early chronic phase chronic myeloid leukemia: experience from a developing country Leuk Lymphoma 49 554 558 10.1080/10428190701824585 (Pubitemid 351298341)
6. HM Kantarjian M Talpaz S O'Brien 2002 Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results Clin Cancer Res 8 2177 2187
7. Y Nannya H Yokota Y Sato 2008 Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan Int J Hematol 88 159 164 10.1007/s12185-008-0111-6
8. M Baccarani G Saglio J Goldman 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 1809 1820 10.1182/blood-2006-02-005686 (Pubitemid 44394987)
9. F Palandri I Iacobucci F Quarantelli 2007 Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase Haematologica 92 1579 1580 10.3324/haematol.12033 (Pubitemid 350144139)
10. J Sessions 2007 Chronic myeloid leukemia in 2007 J Manag Care Pharm 13 4 7
11. Y Qin B Jiang Q Jiang 2009 Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up Ann Hematol 88 1 37 41
12. PH Fitzgerald 1991 Complex Ph translocations in chronic myeloid leukemia Cancer Genet Cytogenet 55 129 131 10.1016/0165-4608(91)90248-S
13. KS Reddy VA Sulcova 2000 FISH study of variant Philadelphia rearrangements Cancer Genet Cytogenet 118 121 131 10.1016/S0165-4608(99)00187-9 (Pubitemid 30169213)
14. AG Reid BJ Huntly C Grace 2003 Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia Br J Haematol 121 419 427 10.1046/j.1365-2141.2003.04291.x (Pubitemid 36628333)
15. E Kolomietz J Al-Maghrabi S Brennan 2001 Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis Blood 97 3581 3588 10.1182/blood.V97.11.3581
16. S Kreil M Pfirrmann C Haferlach 2007 Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia Blood 110 1283 1290 10.1182/blood-2007-02-074252 (Pubitemid 47281427)
17. MW Deininger J Cortes R Paquette 2007 The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells Cancer 110 1509 1519 10.1002/cncr.22936 (Pubitemid 47463065)
18. H Yoshida T Kunisada T Grimm 2001 Review: melanocyte migration and survival controlled by SCF/c-kit expression J Investig Dermatol Symp Proc 6 1 5 10.1046/j.0022-202x.2001.00006.x
19. E Buchdunger CL Cioffi N Law 2000 Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 139 145
20. KW Leong TC Lee AS Goh 2004 Imatinib mesylate causes hypopigmentation in the skin Cancer 100 2486 2487 10.1002/cncr.20267 author reply 7-8
21. S Cang D Liu 2008 P-loop mutations and novel therapeutic approaches in imatinib failures in chronic myeloid leukemia J Hematol Oncol 1 15